Heart Disease

Canadian biotech company begins two studies on cholesterol combination therapy

Published in Medical Letter on the CDC and FDA, November 7th, 2004

Magistral Biotech (MBS) announced two new multi-center clinical studies that will study the effectiveness of Magistral's over-the-counter, cholesterol-lowering drug Libracol when taken concomitantly with Lipitor, Canada's biggest-selling statin, which is marketed by Pfizer.

Andre Aube, Magistral's president and CEO said, "we would not risk pairing our product with a drug of the caliber of Lipitor unless we were highly confident that we would obtain a superior efficacy rate than with the drug alone, while at the same time preventing side effects." This clinical study will compare the effects of the two products in combination therapy with results obtained by patients...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-11-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry